Holocene Advisors
JAZZ icon

Holocene Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Holocene Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-240,000
Closed -$39.6M – 865
2020
Q4 		$39.6M Buy
240,000
+10,000
+4% +$1.49M 0.25% 134
2020
Q3 		$32.8M Buy
+230,000
New +$28.5M 0.25% 130

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Holocene Advisors's JAZZ Position: Q1 2026 in Review

Holocene Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 24% in Q1 2026, buying an estimated $25.2M and bringing the position to 733,905 shares worth $139M. The position accounts for 0.33% of the portfolio, ranked #84.

Holocene Advisors first reported a position in JAZZ in Q4 2017 and has held it in 13 quarters since. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Holocene Advisors held 733,905 shares of Jazz Pharmaceuticals worth $139M as of Q1 2026.
  • Holocene Advisors bought 144,170 Jazz Pharmaceuticals shares in Q1 2026, an estimated $25.2M.
  • Jazz Pharmaceuticals made up 0.33% of Holocene Advisors's portfolio in Q1 2026, its #84 holding.
  • Holocene Advisors first reported a position in Jazz Pharmaceuticals in Q4 2017 and has held it in 13 quarters since.
  • 571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Holocene Advisors's 13F filing for Q1 2026, filed 15 May 2026.